arrow Log In to View Account     |      
Johns Hopkins Medicine
Hopkins Logo

Disclaimer: CME certification for these activities has expired. All information is pertinent to the timeframe in which it was released.

Neurodegeneration and Neuroprotection in Multiple Sclerosis

To examine the clinical markers of disease progression in multiple sclerosis, evaluate the role of various imaging modalities in monitoring neurodegeneration and neuroprotection, and delineate potential neuroprotective therapeutic strategies.

This activity is designed for neurologists, neuropathologists, neuroradiologists, and other experts involved in the treatment of multiple sclerosis. No prerequisites required.

The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity. At the conclusion of this activity, participants should be able to:

  • Understand and apply clinical and MRI markers of disease progression in multiple sclerosis.
  • Review the role of imaging in monitoring neurodegenaration and neuroprotection in multiple sclerosis.
  • Evaluate current and future therapeutic strategies aimed at neuroprotection in multiple sclerosis.

The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 2 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

The estimated time to complete this educational activity:  2 hours.

Release date: March 15, 2004. Expiration date: March 15, 2006.

The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

This program is supported by an unrestricted educational grant from Biogen Idec.

Full Disclosure Policy Affecting CME Activities:
It is the policy of the Johns Hopkins University School of Medicine that the faculty and sponsor disclose real or apparent conflict of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Detailed disclosure will be made in the course handout materials.


    Peter A. Calabresi, MD
    Director, MS Center
    Associate Professor of Neurology
    Johns Hopkins University
    Baltimore, Maryland

    Jeffrey Greenstein, MD
    Multiple Sclerosis Institute
    Philadelphia, Pennsylvania


    Raymond Dingledine, PhD
    Emory University School of Medicine
    Atlanta, Georgia

    Joseph Frank, MD, MS
    National Institutes of Health
    Bethesda, Maryland

    John Griffin, MD
    The Johns Hopkins Hospital
    Baltimore, Maryland

    Marion Murray, PhD
    Drexel University College of Medicine
    Philadelphia, Pennsylvania
    Cedric Raine, PhD, DSc
    Albert Einstein College of Medicine
    Bronx, New York

    Richard Rudick, MD
    The Cleveland Clinic
    Cleveland, Ohio

    Peter Stys, MD
    Ottawa Health Research Institute
    Ottawa, Ontario, Canad

    Bruce Trapp, PhD
    The Cleveland Clinic
    Cleveland, Ohio

Johns Hopkins Advanced Studies in Medicine (ISSN-1558-0334), is published by ASiM CE, LLC, d/b/a ASiM, PO Box 340, Somerville, NJ 08876. (908) 253-9001. Copyright ©2017 by ASiM CE, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of ASiM CE LLC.